IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11572353 B1

PDFFull Text
Date of Patent:
Feb. 07, 2023

Filed:

Jul. 07, 2021

Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof

Applicant:

Beijing Innocare Pharma Tech Co., Ltd., Beijing, CN;

Inventors:

Xiangyang Chen, Beijing, CN;

Yingxiang Gao, Nanjing, CN;

Norman Xianglong Kong, Nanjing, CN;

Assignee:

Beijing Innocare Pharma Tech Co., Ltd., Beijing, CN;

Attorneys:

Perkins Coie LLP

Viola Kung

Primary Examiner:

Kamal A Saeed

Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61P 35/00 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); A61K 31/454 (2006.01); A61K 31/4155 (2006.01); C07D 401/04 (2006.01); A61K 31/415 (2006.01); C07D 401/06 (2006.01); C07D 231/14 (2006.01); C07D 231/44 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/454 (2013.01); A61P 35/00 (2018.01); C07D 231/14 (2013.01); C07D 231/44 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 405/14 (2013.01);
Abstract

The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or preventing FGFR-associated diseases, particularly tumors, wherein the definition of each substituent group in general formula (I) is the same as that in the description.

Find Patent Forward Citations

Loading…